ONL Therapeutics LLC is developing a peptide antagonist of Fas-mediated apoptosis that could become the first pharmacotherapy to prevent vision loss associated with non-exudative retinal detachment. The company expects its products would be used as an adjunct to surgery or drugs that correct the detachment but do not preserve photoreceptors.

Age, injury and diseases such as age-related macular degeneration (AMD) can cause the retina to detach from the retinal pigment epithelium (RPE) layer. Retinal detachment can lead to vision loss caused in part by interruption of nutrient and waste transport between the RPE and photoreceptor cells of the retina responsible for capturing and transducing light.